HomeCompareORTX vs MO

ORTX vs MO: Dividend Comparison 2026

ORTX yields 11.98% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $36.0K in total portfolio value· pulled ahead in Year 8
10 years
ORTX
ORTX
● Live price
11.98%
Share price
$16.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.1K
Annual income
$2,528.78
Full ORTX calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ORTX vs MO

📍 MO pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORTXMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORTX + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORTX pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORTX
Annual income on $10K today (after 15% tax)
$1,017.96/yr
After 10yr DRIP, annual income (after tax)
$2,149.46/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $23,485.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORTX + MO for your $10,000?

ORTX: 50%MO: 50%
100% MO50/50100% ORTX
Portfolio after 10yr
$62.1K
Annual income
$16,343.97/yr
Blended yield
26.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ORTX
Analyst Ratings
6
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-3.3
Piotroski
5/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORTX buys
0
MO buys
0
No recent congressional trades found for ORTX or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORTXMO
Forward yield11.98%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$44.1K$80.1K
Annual income after 10y$2,528.78$30,159.17
Total dividends collected$18.5K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ORTX vs MO ($10,000, DRIP)

YearORTX PortfolioORTX Income/yrMO PortfolioMO Income/yrGap
1$11,898$1,197.60$10,570$780.30+$1.3KORTX
2$14,062$1,331.65$11,381$1,032.90+$2.7KORTX
3$16,517$1,470.94$12,535$1,392.73+$4.0KORTX
4$19,288$1,614.74$14,193$1,920.91+$5.1KORTX
5$22,401$1,762.27$16,618$2,723.68+$5.8KORTX
6$25,882$1,912.75$20,263$3,993.80+$5.6KORTX
7$29,759$2,065.39$25,936$6,098.36+$3.8KORTX
8← crossover$34,061$2,219.43$35,166$9,775.01$1.1KMO
9$38,820$2,374.13$51,026$16,597.78$12.2KMO
10$44,066$2,528.78$80,113$30,159.17$36.0KMO

ORTX vs MO: Complete Analysis 2026

ORTXStock

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Full ORTX Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ORTX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORTX vs SCHDORTX vs JEPIORTX vs OORTX vs KOORTX vs MAINORTX vs PMORTX vs BTIORTX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.